Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

While strategies such as chemotherapy and immunotherapy have become the first-line
standard therapies for patients with advanced or metastatic cancer, acquired resistance is …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …